US tariff uncertainty on innovative medicines
Potential tariffs on patented drug imports into the US could impact Sun Pharma's innovative portfolio, though generics are expected to be excluded.
SUNPHARMA / Q2-FY26 / risks
Keep the risk register visible.
Sunpharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Lenalidomide revenue decline
Lenalidomide sales have dropped YoY and are expected to be minimal in the second half, impacting US generics revenue.
Higher effective tax rate normalization
ETR increased to 24.7% from 15.8% YoY due to expiry of tax benefits, expected to hover around 25%, pressuring net profit growth.
Competition in alopecia areata market
Stagnation in prescriptions for existing targeted treatments could hinder Leqselvi's uptake, though management expects market growth.